IDH1 Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
46Targets
958Trials
16Drugs
0Datasets
4,188Sources
10,439Claims
10,589Evidence
1,574Hypotheses
HYPOTHESISproposedtarget

enasidenib binds KDM6A (Boltz-2 iPTM=0.861)

Description

Boltz-2 structural prediction yields iPTM=0.861 for enasidenib × KDM6A. Flagged for orthogonal validation (Chai-1).

Rationale

iPTM ≥ 0.60 promotes hit into hypothesis shortlist for experimental follow-up.

Supporting evidence (1)

  • 366d792f-f9e9-4898-93a8-be631b7fd620

Related claims (0)

No related claims found.